These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33250513)

  • 61. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
    Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
    Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
    Polusani SR; Cortez V; Esparza J; Nguyen HN; Fan H; Velagaleti GVN; Butler MJ; Kinney MC; Oyajobi BO; Habib SL; Asmis R; Medina EA
    Int J Cancer; 2021 Jun; 148(12):3032-3040. PubMed ID: 33521927
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
    Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
    J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
    Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
    Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
    Haertle L; Barrio S; Munawar U; Han S; Zhou X; Simicek M; Vogt C; Truger M; Fernandez RA; Steinhardt M; Weingart J; Snaurova R; Nerreter S; Teufel E; Garitano-Trojaola A; Da Viá M; Ruiz-Heredia Y; Rosenwald A; Bolli N; Hajek R; Raab P; Raab MS; Weinhold N; Haferlach C; Haaf T; Martinez-Lopez J; Einsele H; Rasche L; Kortüm KM
    Clin Cancer Res; 2023 Jan; 29(1):279-288. PubMed ID: 36282272
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
    Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
    [TBL] [Abstract][Full Text] [Related]  

  • 67. URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
    Fan JL; Zhang J; Dong LW; Fu WJ; Du J; Shi HG; Jiang H; Ye F; Xi H; Zhang CY; Hou J; Wang HY
    Cell Death Dis; 2014 Mar; 5(3):e1126. PubMed ID: 24625985
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
    Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
    Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
    Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
    Nara M; Teshima K; Watanabe A; Ito M; Iwamoto K; Kitabayashi A; Kume M; Hatano Y; Takahashi N; Iida S; Sawada K; Tagawa H
    PLoS One; 2013; 8(3):e56954. PubMed ID: 23469177
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
    Bai Y; Su X
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
    Jones RJ; Singh RK; Shirazi F; Wan J; Wang H; Wang X; Ha MJ; Baljevic M; Kuiatse I; Davis RE; Orlowski RZ
    Front Immunol; 2020; 11():1816. PubMed ID: 32903557
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
    Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
    Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
    Sogabe K; Nakamura S; Higa Y; Miki H; Oda A; Maruhashi T; Sumitani R; Oura M; Takahashi M; Nakamura M; Maeda Y; Hara T; Yamagami H; Fujii S; Kagawa K; Ozaki S; Kurahashi K; Endo I; Aihara KI; Nakaue E; Hiasa M; Teramachi J; Harada T; Abe M
    Int J Hematol; 2024 Mar; 119(3):303-315. PubMed ID: 38245883
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Endocytic pathway inhibition attenuates extracellular vesicle-induced reduction of chemosensitivity to bortezomib in multiple myeloma cells.
    Tu C; Du Z; Zhang H; Feng Y; Qi Y; Zheng Y; Liu J; Wang J
    Theranostics; 2021; 11(5):2364-2380. PubMed ID: 33500730
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.
    Wang H; Xiao X; Li Z; Luo S; Hu L; Yi H; Xiang R; Zhu Y; Wang Y; Zhu L; Xiao L; Dai C; Aziz A; Yuan L; Cui Y; Li R; Gong F; Liu X; Liang L; Peng H; Zhou H; Liu J
    Cancer Lett; 2022 Jul; 537():215647. PubMed ID: 35306105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.